During intervention, serum concentrations of SELENBP1 increased by ≥20% in n = 72 of the cardiac patients (96%, Figure 3A), and 68 patients (91%, Figure 3B) surpassed the cut-off at 0.46 nM, determined earlier as the threshold for an increased risk of death or other major adverse cardiac event in patients with suspected myocardial infarction [30]. Here, SELENBP1 is linked to myocardial infarction.